Compare Immunovant Inc. Common Stock (IMVT) vs Liquidia Corporation Common Stock (LQDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Liquidia Corporation Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $28.35 (market cap $5.93B), while Liquidia Corporation Common Stock trades at $34.5 (market cap $2.40B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.5× Liquidia Corporation Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 6 Days and Liquidia Corporation Common Stock for 0 Days on average.
| IMVT | LQDA | |
|---|---|---|
Market Cap | $5.93B | $2.40B |
Volume | 1,242,632 | 2,857,547 |
Sector | Health | Health |
52-Week High | $44.96 | $91.03 |
52-Week Low | $17.41 | $22.02 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.03B | $2.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Immunovant (IMVT) trades at $28.71, down 2.61% with bearish technical signals despite strong analyst support. The company shows no revenue with substantial losses (-$413.84M net income) and negative margins, though it maintains a robust cash position from recent financing. Recent clinical setbacks, including the discontinuation of IMVT-1402 for cutaneous lupus, have pressured the stock, while multiple law firm investigations into potential fiduciary breaches add uncertainty.
The investment case hinges on IMVT-1402's success in other indications like Graves' disease, with a bullish analyst consensus (78% buy ratings) contrasting high execution risks. Key risks include clinical trial outcomes, cash burn, and legal overhangs. The stock's viability depends heavily on pipeline progress against a backdrop of persistent losses and volatile sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →
